Human PD-L1 Alexa Fluor® 647-conjugated Antibody
Human PD-L1 Alexa Fluor® 647-conjugated Antibody Summary
Phe19-Thr239
Accession # Q9NZQ7
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: PD-L1/B7-H1
B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature human B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (2). Within the ECD, human B7-H1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (3). B7-H1 is expressed on
inflammatory-activated immune cells including macrophages, T cells, and B cells (4-7), keratinocytes (8, 9), enothelial and intestinal epithelial cells (8, 10), as well as a variety of carcinomas and melanoma (11, 12). B7-H1 binds to T cell B7-1/CD80 and PD-1 (7, 8, 12-15). It suppresses T cell activation and proliferation (5, 8, 14, 16) and induces the apoptosis of activated T cells (11). It plays a role in the development of immune tolerance by promoting T cell anergy (7, 14) and enhancing regulatory T cell development (16). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (5, 10) and inhibits the development of Th17 cells (16). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (6, 9, 12, 15).
- Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
- Dong, H. et al. (1999) Nat. Med. 5:1365.
- Frigola, X. et al. (2011) Clin. Cancer Res. 17:1915.
- Tamura, H. et al. (2001) Blood 97:1809.
- Chen, L. et al. (2007) J. Immunol. 178:6634.
- Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
- Tsushima, F. et al. (2007) Blood 110:180.
- Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
- Cao, Y. et al. (2010) Cancer Res. 71:1235.
- Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
- Dong, H. et al. (2002) Nat. Med. 8:793.
- Azuma, T. et al. (2008) Blood 111:3635.
- Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
- Park, J.-J. et al. (2010) Blood 116:1291.
- Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
- Herold, M. et al. (2015) J. Immunol. 195:3584.
Product Datasheets
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
Citation for Human PD-L1 Alexa Fluor® 647-conjugated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis
Authors: Gammelgaard, OL;Terp, MG;Kirkin, AF;Johansen, S;Traynor, S;Vever, H;Guldberg, P;Kodahl, AR;Gjerstorff, MF;Ditzel, HJ;
Molecular cancer
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human PD-L1 Alexa Fluor® 647-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human PD-L1 Alexa Fluor® 647-conjugated Antibody and earn rewards!
Have you used Human PD-L1 Alexa Fluor® 647-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image